Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMD Option Income Strategy ETF vs CVS Health Corp — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $45.06, while CVS Health Corp trades at $93.7 (market cap $122.36B). The key difference: CVS Health Corp pays a 2.78% dividend while YieldMax AMD Option Income Strategy ETF pays none, and CVS Health Corp is trading nearer its 52-week high, YieldMax AMD Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMDY | CVS | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.52 | $110.60 |
52-Week Low | $29.80 | $65.51 |
Market Cap | — | $122.36B |
Enterprise Value | — | $184.71B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMDY trades at $45.61, down 0.93% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF has delivered high weekly distributions, with recent dividends ranging from $0.63 to $1.17, but faces concerns over net asset value erosion. Support is seen at $45, with resistance at $47.
The outlook is cautious due to structural NAV erosion risks highlighted by analysts. Investment opportunity lies in high income generation if AMD exhibits gradual volatility, but direct AMD exposure may be preferable for AI-driven upside. Key risks include yield sustainability and dependency on AMD's stock performance.
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
